Cytokinetics price target raised to $101 from $95 at RBC Capital

RBC Capital raised the firm’s price target on Cytokinetics (CYTK) to $101 from $95 and keeps an Outperform rating on the shares. On the likelihood of success for the ACACIA nHCM trial, the firm sees patients being likely to achieve higher doses, a lower dropout rate, and aficamten to be able to thread the therapeutic needle where mavacamten failed, the analyst tells investors in a research note.